Industry
Biotechnology
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 4:14 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 3:51 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 11:02 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 8:39 pm
Portfolio Pulse from Avi Kapoor
May 20, 2024 | 5:28 pm
Portfolio Pulse from Avi Kapoor
May 20, 2024 | 3:37 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 3:36 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 12:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 11:18 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.